We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+39.69%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.16B
AUM Growth
+$655M
Cap. Flow
-$8.33M
Cap. Flow %
-0.26%
Top 10 Hldgs %
29.57%
Holding
149
New
12
Increased
35
Reduced
32
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$68M
2
HUM icon
Humana
HUM
+$58.7M
3
AXNX
Axonics, Inc. Common Stock
AXNX
+$21.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$21M
5
APRE icon
Aprea Therapeutics
APRE
+$19.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$49M
2
ABBV icon
AbbVie
ABBV
+$39.8M
3
SYK icon
Stryker
SYK
+$38.7M
4
MDCO
Medicines Co
MDCO
+$32.8M
5
CI icon
Cigna
CI
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 90.33%
2 Consumer Staples 0.66%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$382B
$174M 5.49%
591,000
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.2B
$137M 4.34%
1,278,000
+45,500
+4% +$4.76M
WCG
3
DELISTED
Wellcare Health Plans, Inc.
WCG
$106M 3.34%
320,500
– –
AMRN
4
Amarin Corp
AMRN
$297M
$99.7M 3.15%
232,500
– –
ISRG icon
5
Intuitive Surgical
ISRG
$127B
$90.2M 2.85%
457,500
– –
JNJ icon
6
Johnson & Johnson
JNJ
$640B
$81.3M 2.57%
557,500
+501,500
+896% +$68M
HCA icon
7
HCA Healthcare
HCA
$90.6B
$69.1M 2.18%
467,500
– –
HUM icon
8
Humana
HUM
$43.9B
$67.8M 2.14%
+185,000
New +$58.7M
EHC icon
9
Encompass Health
EHC
$11.3B
$56.5M 1.78%
1,024,455
– –
BSX icon
10
Boston Scientific
BSX
$68.4B
$54.3M 1.71%
1,200,000
+230,000
+24% +$9.62M
PCRX icon
11
Pacira BioSciences
PCRX
$1.04B
$52.1M 1.65%
1,150,000
– –
EPZM
12
DELISTED
Epizyme, Inc
EPZM
$50.4M 1.59%
2,050,000
+199,900
+11% +$2.97M
TFX icon
13
Teleflex
TFX
$5.96B
$48.9M 1.55%
130,000
– –
PODD icon
14
Insulet
PODD
$11.8B
$44.6M 1.41%
260,500
– –
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.64B
$44.6M 1.41%
345,500
+8,000
+2% +$807K
VRTX icon
16
Vertex Pharmaceuticals
VRTX
$123B
$44.4M 1.4%
203,000
– –
BAX icon
17
Baxter International
BAX
$12.8B
$43.9M 1.39%
525,000
+140,000
+36% +$11.6M
EW icon
18
Edwards Lifesciences
EW
$49.4B
$42.8M 1.35%
550,500
– –
IRTC icon
19
iRhythm Holdings
IRTC
$4.02B
$42.5M 1.34%
624,000
+69,000
+12% +$4.68M
ALNY icon
20
Alnylam Pharmaceuticals
ALNY
$38.3B
$41.9M 1.32%
364,000
+33,500
+10% +$3.34M
PEN icon
21
Penumbra
PEN
$12.6B
$39.8M 1.26%
242,500
– –
ARGX icon
22
argenx
ARGX
$55.2B
$39.7M 1.26%
247,500
+65,800
+36% +$8.9M
EXAS
23
DELISTED
Exact Sciences
EXAS
$38.8M 1.23%
420,000
-11,750
-3% -$1.03M
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$38.7M 1.22%
300,000
+42,500
+17% +$4.1M
ARDX icon
25
Ardelyx
ARDX
$1.24B
$36.4M 1.15%
4,850,000
+1,794,739
+59% +$10.9M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rock Springs Capital Management held 149 positions worth $3.16B, up 26% from $2.51B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2019 filing shows 12 new, 35 increased, 32 reduced and 19 closed positions. Its largest new stake was Humana: 185,000 shares worth $67.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2019 buy was Humana: 185,000 shares worth $67.8M.
  • Rock Springs Capital Management added most to Johnson & Johnson in Q4 2019, an estimated $68M increase.
  • Rock Springs Capital Management's biggest Q4 2019 reduction was Medicines Co, cutting an estimated $32.8M.
  • Rock Springs Capital Management fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $3.16B portfolio in Q4 2019.
  • Rock Springs Capital Management opened 12 new positions and closed 19 in Q4 2019.
  • Rock Springs Capital Management's portfolio value rose 26% quarter-over-quarter to $3.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.